MentionFox
Home › Executive changes › Turn Therapeutics Inc.
Leadership changes · TTRX · SEC Form 8-K, Item 5.02

Leadership changes at Turn Therapeutics Inc. (2026)

Before you join, sell to or invest in Turn Therapeutics Inc.

MentionFox check on Turn Therapeutics Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/turn-therapeutics

Check Turn Therapeutics Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Turn Therapeutics Inc.?

Who joined and who left Turn Therapeutics Inc. (TTRX)? 1 appointment reported on 2026-01-07, each cited to the company's own filing.

Martin Dewhurst was appointed Director of Turn Therapeutics Inc. As of November 14, 2026, Turn Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 7, 2026, naming 1 appointment (Form 8-K, January 7, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

3 more records on Turn Therapeutics Inc. ↓

Sell to companies like Turn Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-01-07

Turn Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-07. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Turn Therapeutics Inc. files it.

Also on the record for Turn Therapeutics Inc.

DateRecordFigureOur pageSource
August 26, 2026Form D, private offering$1.65M soldForm D pageSource
May 13, 2026Crowdfunding filing, Form C-TR—CrowdfundingSource
April 6, 2026Stake report, Schedule 13G, by Bradley Burnam52.76% of the class5%+ stakesSource
April 29, 2025Crowdfunding filing, Form C-AR—CrowdfundingSource
March 25, 2025Crowdfunding filing, Form C-U$15K targetCrowdfundingSource
January 17, 2025Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
December 18, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
November 12, 2024Crowdfunding filing, Form C-U$15K targetCrowdfundingSource
October 22, 2024Crowdfunding filing, Form C$15K targetCrowdfundingSource
August 19, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
July 15, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource

Selling to them or working with them? See who runs Turn Therapeutics Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Turn Therapeutics Inc. and the records around it.

Turn Therapeutics Inc. elsewhere on the record

Want the whole picture on Turn Therapeutics Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Turn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Turn Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-07InDirector8-K, 2026-01-07

Who leads Turn Therapeutics Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Turn Therapeutics Inc.?

New leaders reset buying decisions — get the Full Report on Turn Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Turn Therapeutics Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Turn Therapeutics Inc., with the record behind each one.

Find candidates like Director at Turn Therapeutics Inc.

Every change, in the filing's words

Filed 2026-01-07 · 8-K

Appointed: Martin Dewhurst, Director

On January 7, 2026, the board of directors (the "Board") of Turn Therapeutics Inc. (the "Company") enlarged the Board from five to six members and appointed Martin Dewhurst to the Board, effective immediately.

Also stated in this filing

  • Mr. Dewhurst will serve as an independent Class III director until his term of office expires at the annual meeting of the Company's stockholders in 2028, or until his earlier death, resignation or removal.
  • Mr. Dewhurst will serve as the chair of the compensation committee of the Board.
  • Biographical information for Mr. Dewhurst is set forth below: Martin Dewhurst, age 62, has served as advisor to GHO Capital, a healthcare specialist private equity firm since July 2024.
  • Mr. Dewhurst has been a senior advisor since April 2023 to PJT Partners, a global investment and M&A advisory bank.
  • Mr. Dewhurst has also served as a senior advisor to LightRock, a growth capital fund, since April 2023.
  • Mr. Dewhurst also holds various board positions including at Unilabs Ltd. (since September 2025), KOS AI (since June 2025), Cytovation ASA (since February 2025), Distalmotion (since April 2023) and MedGenome (April 2023 through January 2025).
  • Prior to his various advisory and board roles, Mr. Dewhurst was a senior partner with McKinsey & Co., a leading management consulting firm where he served from 1992 through 2023 and co-led the firm's life sciences practice (2014 to 2021).
  • Mr. Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD, where he graduated on the Dean's List.

Tools for this story

Each opens in a new tab, filled in for Turn Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/turn-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Turn Therapeutics Inc.? Leadership changes (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/turn-therapeutics